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The transcription factor GATA2 is required for expansion and differentiation of 41 
hematopoietic stem cells (HSCs). In mesenchymal stem cells (MSCs) GATA2 blocks 42 
adipogenesis, but its biological relevance and underlying genomic events are unknown. We 43 
report a dual function of GATA2 in bone homeostasis. GATA2 in MSCs binds near genes 44 
involved in skeletal system development and co-localizes with motifs for FOX and HOX 45 
transcription factors, known regulators of skeletal development. Ectopic GATA2 blocks 46 
osteoblastogenesis by interfering with SMAD1/5/8 activation. MSC-specific deletion of 47 
GATA2 in mice increases numbers and differentiation capacity of bone-derived precursors, 48 
resulting in elevated bone formation. Surprisingly, MSC-specific GATA2 deficiency impairs 49 
trabecularization and mechanical strength of bone, involving reduced MSC expression of the 50 
osteoclast inhibitor osteoprotegerin and increased osteoclast numbers. Thus, GATA2 affects 51 
bone turnover via MSC-autonomous and indirect effects. By regulating bone 52 
trabecularization, GATA2 expression in the osteogenic lineage may contribute to the 53 
anatomical and cellular microenvironment of the HSC niche required for hematopoiesis.  54 
 55 
INTRODUCTION 56 
GATA2 belongs to a family of six structurally related zinc finger transcription factors 57 
(GATA1-6) and plays a critical role in hematopoiesis. Mice that lack GATA2 die during 58 
embryonic development due to severe anemia upon impaired proliferation and survival of 59 
early hematopoietic stem cells (HSCs) (1). Expression of GATA2 in HSCs is required for the 60 
expansion of multipotent hematopoietic cells and the formation of mast cells, but was found 61 
dispensable for the terminal differentiation of erythroid cells and macrophages (2). In humans, 62 
germline mutations in GATA2 are associated with the GATA2-deficiency syndrome, which 63 
manifests as a complex array of hematologic, neoplastic, dermatologic, and pulmonary 64 
symptoms that can be accompanied by certain viral infections and congenital deafness (3). 65 
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Acquired mutations have been linked to myelodysplastic syndrome, acute myeloid leukemia, 66 
and to blast crisis transformation of chronic myeloid leukemia (4). 67 
 68 
Besides its expression in hematopoietic precursors, GATA2 is expressed in mesenchymal 69 
stem/stromal cells (MSCs) (5), common precursors for e.g. adipocytes, myocytes, osteocytes 70 
and chondrocytes. In part owing to the embryonic lethality of GATA2-deficient mice, 71 
GATA2's function in MSCs is much less investigated and most insights derive from studying 72 
its role during adipogenesis. GATA2 was shown to block differentiation of both white and 73 
brown precursor cells (5-7) by reducing peroxisome proliferator-activated receptor  (PPAR) 74 
promoter activity and by interfering with CCAAT/enhancer binding protein (C/EBP)-75 
mediated transcription (8). 76 
 77 
Here, we report the first genome-wide analysis of GATA2 binding sites in mesenchymal cells 78 
and implicate this transcription factor in bone homeostasis. GATA2 binds canonical motifs 79 
near genes involved in skeletal development and blocks osteoblastogenesis. Mice that lack 80 
GATA2 specifically in MSCs developed normally but, surprisingly, showed reduced bone 81 
trabecularization and bone strengths involving lower osteoprotegerin (Opg) expression in 82 
MSCs and higher osteoclast numbers. Moreover, MSC-specific deletion of GATA2 reduced 83 
red blood cell counts which may imply a much broader role for GATA2 in the control of 84 
hematopoiesis than previously thought. 85 
 86 
RESULTS 87 
GATA2 regulates and binds the Zfpm1 gene in mesenchymal 3T3-L1 cells. GATA factors 88 
regulate gene expression via their interaction with friend of gata (FOG)/zinc finger protein, 89 
FOG family member (ZFPM) cofactors (9). ZFPM1 is also a transcriptional target of GATA 90 
factors in hematopoietic cells, and binding sites near the Zfpm1 gene locus (+0.7 and +24.4 kb 91 
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of the transcriptional start site (TSS)) have been previously identified in G1E-ER cells, an 92 
erythroid cell line (10). We focused on Zfpm1 in order to identify a functionally relevant 93 
binding site of GATA2 in 3T3-L1 cells, an adipocyte-lineage committed mesenchymal cell 94 
line (11). As previously reported (6, 12), GATA2 is down-regulated during adipogenesis (Fig. 95 
1A, before (day 0) and 14 days after the initiation of differentiation). Similarly, mRNA 96 
expression of Zfpm1 was reduced (Fig. 1B) in accordance with a recent study (13), suggesting 97 
that GATA2 regulates Zfpm1 expression in 3T3-L1 cells. Indeed, retroviral over-expression 98 
of GATA2 in preadipocytes up-regulated ZFPM1 protein (Fig. 1C). We performed chromatin 99 
immunoprecipitation (ChIP) of endogenous GATA2 and found that binding was conserved at 100 
+0.7 kb but not +24.7 kb of the Zfpm1 TSS in 3T3-L1 cells and absent in adipocytes (Fig. 101 
1D), consistent with the low expression of GATA2 after differentiation. An upstream site (-102 
1.4 kb) served as negative control. GATA2 binding to +0.7 kb of Zfpm1 was used as 103 
control/validation site for all further ChIP experiments. Input and GATA2-enriched chromatin 104 
of undifferentiated 3T3-L1 cells (>5 fold enriched at +0.7 of Zfpm1) was subjected to high-105 
throughput sequencing (ChIP-seq).  106 
 107 
GATA2 binds genomic WGATAR motifs and is enriched at skeletal development genes. 108 
We identified a total of 1,975 peaks (false discovery rate (FDR) 1%) (Table S1) and more 109 
than 90% localized to intergenic and intronic regions. Only a small fraction mapped to 110 
proximal promoters (73 peaks within 3 kb 5' of the TSS) (Fig. 1E). Binding to five randomly 111 
selected sites near the genes Prickle, Tinag, Cdk4, Tsen and RetSat was validated and 112 
confirmed by ChIP-qPCR (data not shown). De novo motif analysis of genome-wide GATA2 113 
binding sites by SeqPos (14) revealed that GATA containing sequences represented the top 114 
three motif clusters (Fig. 1F, + and – strands), matching the consensus WGATAR motif 115 
(W=T or A; R=G or A) (15-17) to a high extent. Of note, also E- box motifs of (CANNTG)-116 
WGATAR-containing composite elements, known to be important for GATA's cooperative 117 
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function with other transcription factors (16, 18), were enriched although much less 118 
significantly (Fig. 1G, top panel). Interrogating known binding motifs in peak regions 119 
identified either GATA factors or transcription factors with binding motifs that contain 120 
GATA (Fig. 1G, bottom panel). Binding sites showed evolutionary conservation when 121 
assessed by phastCons, which is based on a two-state phylogenetic hidden Markov model (19) 122 
(Fig. 1H). Next, nearby genes (located 70 kb 5`or 3`of GATA2 binding sites, n=2,230 genes, 123 
Table S2) were analyzed by gene ontology analysis and enriched to pathways involving 124 
transcription, nucleic acids, and nitrogen compound metabolic process (Fig. 1I). Strikingly, 125 
one of the top-ranking pathways mapped to skeletal system development (Fig. 1I, n=56 genes, 126 
Table S2), suggesting a role for GATA2 in osteoblast differentiation and bone homeostasis. 127 
Binding to six randomly selected sites near genes of this pathway (Foxc2, Cobl, Sfrp2, Igsf10, 128 
Man2a1 and Ptgs2) was validated and confirmed by ChIP-qPCR (data not shown). 129 
 130 
HSC versus MSC-specific binding of GATA2. We then intersected the 3T3-L1 GATA2 131 
cistrome with a published data set of GATA2 binding sites in FDCPmix cells (20), a bone 132 
marrow-derived cell line with HSC-like characteristics (21). The number of peaks/binding 133 
sites (Table S1) and nearby genes (Table S2) were much higher in these cells (FDR 1%) and 134 
overlapped with about 54% of the genes within 70 kb of GATA2 binding in 3T3-L1 cells 135 
(Fig. 2A). 3T3-L1-specific, overlapping and mHSC-specific genomic GATA2 binding sites 136 
were mapped to H3K4me1, H3K27ac, and chromatin DNase I hypersensitivity sequencing 137 
(DHS) data of 3T3-L1 preadipocytes (Fig. 2B). We found strong enrichment of H3K4me1 138 
and H3K27ac on both 3T3-L1-specific and overlapping GATA2 binding sites, whereas DHS 139 
was strongest on overlapping sites, followed by 3T3-L1 and mHSC-specific sites. These 140 
results support the notion that cell-type specific chromatin accessibility determines GATA2 141 
binding. Moreover, when analyzed separately for gene ontology, 'embryonic skeletal system 142 
morphogenesis' and 'development' were now the two top ranking pathways of genes located 143 
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near GATA2 sites that are specific to 3T3-L1 cells (n=1,011 genes), whereas both 144 
overlapping genes (n=1,219 genes) and genes near HSC-specific binding sites (n=6,316) 145 
mapped to other, skeletal system-unrelated pathways (Fig. 2C, left panel, corresponding genes 146 
in Table S2). We then asked which motifs besides WGATAR enrich to cell type-specific 147 
peaks. Motifs for transcription factors of the FOX and HOX family, known regulators of 148 
neural crest cells and skeletal development (22, 23) were found near 3T3-L1-specific, 149 
whereas motifs for a variety of factors involved in hematopoiesis were identified near HSC-150 
specific binding sites (Fig. 2C, right panel). Thus, GATA2 appears to co-localize with 151 
specific lineage-determining transcription factors that may prime and/or facilitate cell type-152 
selective binding. GATA2 binding sites near Zfpm1 and Ccna1 were conserved in 153 
C3H10T1/2 cells (Fig. 2D, left panel) that, in contrast to adipocyte lineage-committed 3T3-L1 154 
cells, are mesenchyme-derived cells that exhibit multipotency (24). GATA2 ChIP-seq in these 155 
cells identified 1,517 binding sites (FDR 1%) (Table S1) and the GATA consensus motif as 156 
the most enriched sequence (Fig. 2D, right panel top). Of the 1,936 genes located near 157 
GATA2 binding sites in C3H10T1/2 cells (Table S2), 989 overlapped with those in 3T3-L1 158 
(Fig. 2D, right panel bottom). As expected, heatmap visualization showed a much higher 159 
overlap of GATA2 binding sites between the two mesenchymal cell lines compared to 160 
binding in HSCs (Fig. 2E). 161 
 162 
GATA2 blocks osteoblastogenesis and impairs SMAD signaling. To test the hypothesis 163 
that GATA2 regulates osteoblast differentiation, we retrovirally over-expressed GATA2 in 164 
C3H10T1/2 cells (Fig. 3A) and stimulated osteoblastic conversion. Remarkably, ectopic 165 
GATA2 strongly suppressed osteoblastogenesis, when assessed by alkaline phosphatase 166 
(ALPL) staining, Alizarin staining of calcium deposition, and by the expression of osteoblast 167 
marker genes after 8 days of differentiation (Fig. 3B and 3C, respectively). Since Wnt- and 168 
SMAD-signaling are pivotal in controlling osteoblast differentiation (25, 26), we tested 169 
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whether ectopic GATA2 would interfere with these pathways. GATA2 blocked the BMP2-170 
induced activation of a SMAD1/5/8 luciferase reporter (Fig. 3D) but had no discernable effect 171 





 MSCs from subcutaneous white adipose tissue (sqWAT) and ectopically expressed 173 
GATA2 in these primary cells (Fig. 3F). Affymetrix gene expression-profiling showed that 174 
ectopic expression of GATA2 in undifferentiated cells regulated 805 of the 2,230 genes with 175 
nearby GATA2 binding (Table S3) and 41 of 102 (q < 0.05) genes defined by the GO terms 176 
related to skeletal system development (Fig. 3G, Table S2), and several SMAD's and 177 
respective target genes (Fig. 3H). Since the majority of these genes were down-regulated 178 
(n=29 vs. 12), GATA2 seems to function primarily as a repressor of genes involved in 179 
skeletal development/osteoblast differentiation. Moreover, GATA2 also potently inhibited 180 
osteoblastogenesis in primary MSCs as shown by reduced ALPL and Alizarin staining and 181 
lower expression of osteoblast marker genes after 8 days of differentiation (Fig. 3I and 3J). 182 
Taken together, GATA2 inhibits osteoblastogenesis of MSCs, at least in part, by interfering 183 
with genes related to skeletal development such as BMP2-driven SMAD-signaling. 184 
 185 
MSC-specific GATA2 deletion increases precursor cell numbers in bone and enhances 186 
in vitro osteoblastogenesis. We then addressed the effects of GATA2 deficiency by crossing 187 
mice with floxed Gata2 alleles (27) with Prx1-Cre mice deleting specifically in MSCs but not 188 
CD45
+
 hematopoietic or CD31
+
 endothelial cell populations (28, 29). This strategy allowed 189 
deletion in MSCs derived from bone and sqWAT, but not in those of eWAT or brown adipose 190 
tissue (BAT) (Fig. 4A), consistent with previous reports on the Prx1-Cre line (30, 31). 191 
Notably, GATA2 deletion was not detectable when analyzing whole tissue mRNA, 192 
presumably due to GATA2 expression in cell types that are not targeted by Prx1-Cre (data not 193 
shown). Loss of GATA2 in sqWAT MSCs was confirmed on protein level (Fig. 4B) and did 194 
not induce an up-regulation of other GATA family members as a compensational response 195 
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MSCs (Fig. 4D), precursor populations with high adipogenic and 197 
osteoblastogenic capacity, respectively (29). When assessed for in vitro osteoblast 198 





 cells lacking GATA2 showed a striking enhancement of osteoblast differentiation 200 







MSCs (Fig. 4G and 4H). Thus, deletion of GATA2 increases the numbers of bone-residing 202 




precursors. Interestingly 203 














when assessed by Oil Red O lipid staining and the expression of adipocyte marker genes (data 206 
not shown). 207 
 208 
MSC-specific GATA2 deletion impairs trabecularization and mechanical strength of 209 
bone. We next analyzed bone structure of mice with MSC-specific GATA2 deletion and 210 
found no differences in cartilage or bone morphogenesis of day E18.5 fetuses (Fig. 5A, top 211 
panel), or in growth plate morphology/ height (Fig. 5A, bottom panels) and tibia length (17.6 212 
± 0.23 mm in Cre (-) vs. 17.8 ± 0.14 mm in Cre (+), n=4,4) at three months of age. However, 213 
µCT analyses revealed a profound impairment of tibial trabecularization in the transitional 214 
section from the meta- to the diaphysis of three months old mice (Fig. 5B) with bone surface 215 
and trabeculae numbers strongly reduced (Fig. 5C). This observation was surprising and 216 
opposite to the phenotype we would have predicted from our findings regarding the increase 217 
in numbers and osteoblastic potential of bone-resident MSCs. Three-point bone bending, 218 
which depends predominantly on mid-diaphysis structure, showed that femora of aged mice 219 
with MSC-specific GATA2 deletion exhibited reduced cortical strength (Fig. 5D). To 220 
determine whether increased MSC numbers (Fig. 4D) could improve bone regeneration, we 221 
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assessed healing of a stabilized tibia fracture histomorphometrically but found no significant 222 
differences in mineralized and cartilaginous tissues between genotypes that would point 223 
towards an altered healing process (data not shown). Hence, GATA2 expression in bone-224 
resident MSCs is required for bone trabecularization and its cortical strength but dispensable 225 
for the regeneration of fractured bone. 226 
 227 
MSC-specific GATA2 deletion activates osteoclasts involving reduced osteoprotegerin 228 
and alters blood cell counts. In order to identify the reason for impaired trabecularization in 229 
mice with MSC-specific GATA2 deletion, we first investigated bone anabolism and 230 
determined mineral apposition rate (MAR) by calcein double staining. MSC-specific deletion 231 
of GATA2 increased MAR in trabecular bone (Fig. 6A) whereas there was no effect in 232 
cortical bone (data not shown). This indicates that reduced trabecularization is unlikely due to 233 
reduced bone formation. We next assessed whether differentiation of GATA2-deficient bone-234 





 cells was indeed enhanced (increased Oil Red staining and mRNA 236 
expression of the adipogenic marker genes Ppar2 (18.7 ± 1.99 fold) , Cebpa (6.8 ± 0.92 237 
fold), aP2 (33.5 ± 2.26 fold) in Cre (+) compared to Cre (-) cells, after the induction of 238 
differentiation). In contrast, H&E staining of bone sections and mRNA expression of 239 
adipocyte marker genes in bone failed to support a significant increase in bone marrow 240 
adipocytes (data not shown). Instead, bone mRNA expression of osteoclast marker genes and 241 
the number of osteoclasts determined as tartrate-resistant acid phosphatase (TRAP)-positive, 242 
multinucleated cells was increased (Fig. 6B and 6C). This suggests that impaired 243 
trabecularization could be caused by an imbalance of catabolic over anabolic bone cells. Since 244 
GATA2 deletion in these mice is specific to the mesenchymal lineage, we analyzed known 245 
osteoblast-derived signals that affect osteoclast differentiation and activity. Expression of 246 
receptor activator of nuclear factor kappa B ligand (Rankl) (32, 33) and colony stimulating 247 
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factor 1 (Csf1) (34) were unchanged in bone of GATA2-deleted mice, whereas that of Opg 248 
(35) was reduced by 50% (Fig. 6D). Since OPG is a decoy receptor for the osteoclast-249 
differentiation factor RANKL (36, 37), this gene expression pattern is consistent with the 250 
observed increase in osteoclasts. Thus, reduced trabecularization may be a consequence of 251 
lower expression of Opg and increased osteoclast differentiation. To investigate whether Opg 252 
is a direct transcriptional target of GATA2 in MSCs, we analyzed GATA2 binding near its 253 
genomic locus and found two binding sites at 13.0 and 75.4 kb upstream of its TSS in 254 
C3H10T1/2 cells but not in HSCs (Fig. 6E, validated by ChIP-qPCR in Fig. 6F). Deleting 255 





 MSCs (Fig. 6G). A similar down-regulation was observed in mouse 257 




 MSCs derived from sqWAT in an adenoviral 258 
Cre-dose and time-dependent manner (data not shown), indicating that the regulation of Opg 259 
by GATA2 is cell-autonomous and conserved between different mesenchymal cell types. To 260 
address whether altered morphology and metabolism of trabecular bone of mice with MSC-261 
specific GATA2 deletion affects hematopoiesis, we analyzed blood parameters. GATA2 262 
deletion caused a slight reduction in red blood cell count and hemoglobin levels whereas there 263 
was no difference in the numbers of white blood cells and platelets (Fig. 6H). 264 
 265 
DISCUSSION 266 
In this study, we provide the first genome-wide analysis of GATA2 binding sites in 267 
mesenchymal cells and identify a novel function of this transcription factor in establishing 268 
bone trabecularization. The most common sequences in genomic regions enriched by GATA2 269 
resemble the canonical WGATAR motif, suggesting that GATA2 affects transcription in 270 
these cells predominantly via direct DNA binding rather than being tethered to other 271 
transcription factors like C/EBPs (8), or as component of recently identified mega 272 
transcription factor complexes (38). Binding sites in MSCs, but not in HSCs, were enriched 273 
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near genes involved in skeletal system development and morphogenesis, and co-localized 274 
with binding motifs of the FOX and HOX family of transcription factors. This suggests that 275 
certain lineage determining factors pioneer for MSC-specific GATA2 binding at short 276 
recognition sequences such as the WGATAR motif that occurs in the genome rather 277 
frequently. Since MSC-specific, but not HSC-specific GATA2 binding sites associated 278 
strongly with H3K4me1 and H3K27ac in mesenchymal cells, chromatin accessibility could 279 
account for cell type-specific binding. 280 
 281 
Enrichment of binding sites near genes involved in skeletal system development and 282 
morphogenesis prompted us to explore GATA2's role during osteoblast differentiation. 283 





 precursor cells enhanced osteoblast differentiation, at least in part by 285 
interfering with BMP-driven SMAD signaling. Besides osteoblast differentiation, MSC-286 
specific GATA2 deletion also increased the number of mesenchymal precursor cells in bone 287 




 precursor cells in vitro. Thus, GATA2's 288 
function is to limit precursor cell numbers in bone and the osteoblastic/adipogenic 289 
differentiation of certain precursor populations. Intriguingly, deletion of GATA2 in sqWAT-290 
residing precursors did not affect precursor numbers, their adipogenic differentiation, or 291 
sqWAT mass, suggesting that GATA2 is biologically more relevant for proliferation and 292 
differentiation of MSCs in bone, rather than for those residing in WAT. 293 
 294 
At first we were surprised that MSC-specific deletion of GATA2, despite increased numbers 295 
of bone-residing precursor cells and enhanced osteoblast differentiation, led to reduced bone 296 
trabecularization and lower mechanical strength of bone. Bone formation within trabecular 297 
sections was increased but accompanied by elevated numbers of osteoclasts, suggesting that 298 
anabolic but also catabolic processes were activated upon loss of GATA2 in MSCs. Our 299 
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finding that GATA2 is required for full expression of the osteoclastogenesis inhibitor Opg in 300 




 precursors, suggests that MSC-specific 301 
loss of GATA2 shifts the balance of anabolism versus catabolism within certain bone sections 302 
towards catabolism, thus interfering with trabecularization. This is further supported by the 303 
phenotype of Opg deficient mice that display a similar but much more severe trabecular 304 
impairment and cortical bone porosity (39, 40). Since osteoclasts are derived from HSCs and 305 
GATA2-deficient osteoclast precursor cells exhibit reduced proliferation (41-43), GATA2 306 
controls osteoclastogenesis not only in a direct and cell-autonomous manner, but also 307 
indirectly- via the regulation of Opg expression from cells of the mesenchymal lineage. 308 
Another interesting observation is that Opg deficiency in mice causes hearing loss (44), 309 
suggesting that deafness due to mutation of GATA2 in humans (3) could involve reduced 310 
OPG expression. Moreover, mutated OPG in humans can result in defective vestibular 311 
morphology (45), and malformations in similar structures have been found in GATA2 312 
deficient mice (27). Notably, other signals of the osteoblasts and osteoclasts crosstalk may be 313 
affected by loss of GATA2 in MSCs and thereby involved in the observed phenotype. Further 314 
research is needed to elucidate the contribution of these factors. 315 
 316 
Our study is in accordance with some of the findings of Li et al. (46), who observed increased 317 
osteoblastogenesis of GATA2-deficient MSCs derived from bone. Mechanistically, this was 318 
attributed to increased Wnt/-catenin signaling (46), a pathway whose activity we found not 319 
affected by ectopic GATA2 expression. Both Li et al. and Kamata et al. observed reduced 320 
MSC proliferation upon loss of GATA2 or siRNA-mediated depletion of GATA2 in human 321 
MSCs (5), respectively. In contrast, we found increased numbers of bone-residing precursor 322 
cells in mice with MSC-specific deletion of GATA2, suggesting that MSC proliferation may 323 
be influenced by the bone microenvironment. The most striking difference is in regard to 324 
reduced trabecularization, since Li et al. reported the opposite finding of higher bone mass 325 
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and trabecularization upon the loss of GATA2 in MSCs, despite using the same genetic 326 
mouse model (46). The reason for this is currently unknown but may involve the spatial 327 
stratifications we applied to our µCT analyses. Moreover, Li et al. found increased bone 328 
marrow adiposity whereas we and others (47) did not, which is another aspect that requires 329 
further studies to consolidate these contradictory results. 330 
 331 
An intriguing notion concerns the expression of GATA2 in different developmental lineages 332 
and why GATA2, as one of the master regulators of HSC differentiation, controls 333 
mesenchymal precursors especially in bone. A plausible hypothesis could derive from the 334 
greatly advanced understanding of the adult marrow HSC niche (48), where both 335 
hematopoietic and mesenchymal cells warrant HSC self-renewal, proliferation, and 336 
differentiation (49). GATA2 expression in HSCs is required for their expansion and the 337 
formation of mast cells, whereas GATA2 in MSCs may support developing the anatomical 338 
and cellular microenvironment of the niche. The slight reduction in red blood cell counts upon 339 
MSC-specific GATA2 deletion could be secondary to reduced bone trabecularization and an 340 
impaired HSC niche. Notably, accelerated osteoclastogenesis and osteoporosis in Opg-341 
deficient mice was accompanied by reduced HSC mobilization and colony formation (50), 342 
supporting a link between higher osteoclast number/activity, the microenvironment of the 343 
niche, and blood cell formation. Support for a role of GATA2 comes from a study that 344 
identified compromised colony formation of hematopoietic progenitor cells from mice lacking 345 
GATA2 in MSCs and lower numbers of common myeloid progenitors after the 346 
transplantation of CD45
+
 cells into mice that lacked GATA2 in bone marrow (47). On the 347 
other hand, lower Opg expression upon GATA2 deletion in MSCs could directly hinder HSC 348 
expansion since OPG was shown to enhance the expansion of hematopoietic progenitor cells 349 
in vitro (51). These observations warrant further research to complete our understanding of 350 
the interconnection of lineage-specific actions of GATA2. 351 
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In summary, we have identified genome-wide binding sites of GATA2 in mesenchymal cells 353 
and a novel function of GATA2 in bone trabecularization and mechanical strength, suggesting 354 
that GATA2-deficiency syndrome patients may be more vulnerable to bone fractures. 355 
Moreover, our study could imply a therapeutic potential of correcting an abnormal skeletal 356 
system and bone morphology to treat certain blood diseases. 357 
 358 
MATERIAL AND METHODS 359 
Mouse experiments 360 
All experimental animal procedures were in accordance with institutional guidelines and 361 
approved by the 'Landesamt für Gesundheit und Soziales' in Berlin, Germany. Mice were 362 
housed under 12/12 hours light/dark cycles and fed standard chow (ssniff R/M-H). C57BL/6 363 
females with floxed Gata2 alleles (27) were mated with male B6.Cg-Tg(Prrx1-cre)1Cjt/J (28) 364 
(Jackson laboratory, stock nr. 005584) for deletion in MSCs. Male mice were used for 365 
experiments. 366 
 367 
Culture and differentiation of cell lines 368 
C3H10T1/2 and 3T3-L1 cells (ATCC) were cultured according to the provider's instructions. 369 
3T3-L1 cells were differentiated to adipocytes by incubation with insulin, dexamethasone, 370 
and 3-isobutyl-1-methylxanthine as previously described (52). C3H10T1/2 cells were 371 
differentiated to osteoblasts using 300 ng/ml BMP-2 (eBioscience), 10 mM -372 
glycerophosphate and 50 µg/ml ascorbic acid (Sigma) for 8 days. Calcium phosphate and 373 
alkaline phosphatase staining was performed using specific reagents (Alizarin Red S (Sigma) 374 
and the BCIP/NBT kit (US Biologicals)). 375 
 376 
Isolation, FACS, culturing, and differentiation of primary cells 377 
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Isolation and maintenance of sqWAT-derived MSCs was performed as described elsewhere 378 
(53). In short, male C57Bl/6J mice aged 8-12 weeks were sacrificed and sqWAT isolated. The 379 
tissue was cut into small pieces, digested with collagenase, type II (Sigma), and filtered 380 
through a 70 µm mesh to obtain sqWAT MSCs. Freshly isolated cells were seeded on 6 well 381 
plates and maintained in DMEM with 10% FBS, 1% Pen/Strep (all ThermoFisher), and 10 382 
mM HEPES. Cells were cultivated for at least 2 passages before inducing differentiation. 383 
MSC identity was analyzed by FACS. For differentiation, cells were seeded in 24 or 48 well 384 
plates and grown to ~80% confluency. Osteoblastogenesis was induced by 10 mM ß-385 
glycerophosphate, 50 µg/ml ascorbic acid and 50 ng/ml BMP-2 and culture medium changed 386 
every other day. Bone-derived MSCs were isolated as previously described (29). In brief, 387 
soft-tissue free bones (tibia/femur) were crushed and digested by collagenase, type II 388 
(CellSystems) for 1 hour at 37° C and constant agitation. The digest was stopped by adding 389 
sorting buffer (2% FBS/PBS). The suspension was filtered through a 70 µm mesh, 390 
centrifuged, and the pellet re-suspended in Ammonium-Chloride-Potassium lysis buffer to 391 
eliminate red blood cells. After an additional wash step, cells were re-suspended in sorting 392 
buffer and antibody-labeled (Table S4). Flow cytometry and cell sorting was conducted on a 393 
FACS Aria III cell sorter (BD Biosciences) and analyzed using FlowJo software (Tree Star). 394 
Living cells were gated for lack of PI fluorescence and staining of calcein (Sigma). 395 
Compensation, fluorescence-minus-one control based gating, and FACS-isolation were 396 
conducted as before (54). Freshly isolated cells were maintained and differentiated to 397 
adipocytes or osteoblasts as previously (29). Lipid accumulation was determined by Oil Red 398 
O staining (Sigma) and calcium deposition by 2% Alizarin Red S staining (Carl Roth). Mouse 399 
embryonic fibroblasts were isolated by removing head, limbs, and liver of E13.5 embryos. 400 
The remaining tissue was minced and homogenized using a 18 G syringe and seeded in 401 
culture flasks. Fibroblasts were grown and expanded in AlphaMEM (Sigma) supplemented 402 
with 10% FBS, 1% Pen/Strep. 403 
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Retro and adenoviral infections 405 
The coding sequences of murine GATA2 sequence was cloned downstream of a Kozak 406 
consensus into a retroviral pMSCV vector containing a puromycin resistance cassette (Takara 407 
Clontech) and verified by sequencing. EcoPack 2-293 cells (Takara Clontech) were 408 
transfected with GATA2 or empty pMSCV vectors using Lipofectamine 2000 409 
(ThermoFisher). The retroviral particles-containing media was harvested 48 hours later. The 410 
supernatants were supplemented with 10 µg/ml polybrene and used to infect pre-confluent 411 
C3H10T1/2 or primary sqWAT-derived MSCs for 24 hours. 48 hours later, cells were 412 
cultured in the presence of 1 µg/ml puromycin. Adenoviruses expressing GFP or Cre were 413 
prepared as described previously (55, 56) and equal titers (infectious units (ifu)) used to infect 414 
MSCs (1.25E8 ifu/ml in Fig. 7F) or MEFs (3.2E6 ifu/ml) overnight. 415 
 416 
Transfections and luciferase reporter assays  417 
C3H10T1/2 cells were transfected with pGL4.49 [luc2P/TCF-LEF RE] (Promega) or pGL3-418 
Id1-BRE (57) vectors by Lipofectamine 2000 (ThermoFisher). 16-20 hours later, cells were 419 
stimulated with LiCl (32 mM) or BMP-2 (300 ng/ml) for an additional 4-8 hours and 420 
luciferase activity determined. Firefly activity was normalized to co-expressed renilla 421 
luciferase (Dual Luciferase Reporter Assay, Promega). 422 
 423 
Chromatin immunoprecipitation (ChIP) 424 
ChIP analyses in 3T3-L1 and C3H10T1/2 cells were performed as described previously (56). 425 
Approx. 100 µg of sonicated chromatin extracts were used for each IP and incubated with 10 426 
µg of a GATA2 antibody (sc-9008x, Santa Cruz) overnight. qPCRs were normalized to the 427 
amplification of a fragment of the insulin or 36B4 gene. Primers for ChIP-qPCR are listed in 428 
Table S5. 429 
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ChIP-seq and analyses 431 
Pooled DNA from three independent GATA2 ChIPs was used to generate libraries for deep 432 
sequencing on Illumina HiSeq instrument. High quality reads were removed if aligning to 433 
simple repeat regions and reads were mapped to the mm10 mouse genome assembly. Peaks of 434 
2 independent experiments were called using the MACS2 algorithm (58) with a minimum 435 
cutoff of 1% FDR and combined. Called peaks overlapping with ENCODE blacklisted 436 
regions for mm10 (59) were removed, as well as peaks located in chr10: 106613366-437 
107858706, chr10: 116174799-118176364 or chrX: 143482886-143483277, since these 438 
regions are amplified in 3T3-L1 cells. PhastCons-based average conservation profiles across 439 
peak regions (3000 nt around peak center) were computed with the conservation_plot.py 440 
script from Tao Liu's open source libraries for bioinformatics (60). Peaks were mapped to 441 
neighboring genes within +/- 70 kb using Bedtools windowBed function (61). Genome-wide 442 
localization of enriched peak regions were determined using CEAS package (62). Motif 443 
search was conducted using SeqPos (14). Gene ontology analysis of genes near GATA2 444 
binding site was performed using DAVID (63, 64). A previously published GATA2 ChIP-seq 445 
dataset from murine hematopoietic progenitor cells (20) was analyzed accordingly. 446 
Overlapping peaks were identified using intersectBed from Bedtools (65). DeepTools (66) 447 
was used to generate heatmaps and signal profiles of peak regions (center ±2 kb). H3K4me1 448 
and H3K27ac ChIP-seq data were obtained from (67) GEO: GSE95533. DNase-seq data were 449 
obtained from (68), GEO: GSE27826. 450 
 451 
Blood analysis 452 
Complete blood cell counts were performed with peripheral blood samples obtained by facial 453 
vein or heart puncture from 6-9 months old male mice, immediately stored in tubes containing 454 
K3-EDTA anticoagulant (Sarstedt) and analyzed on a XS-800i haematology analyser 455 
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(Sysmex) on the same day. A Grubbs’ test based outlier analysis was performed using online 456 
outlier calculator software (Graphpad Prism), and values with a significance level α<0.05 457 
were excluded. 458 
 459 
Protein isolation and immunoblotting 460 
Cellular proteins were isolated in RIPA buffer and separated by SDS page. After incubation
 
461 
with primary antibodies for GATA2 (sc-9008, Santa Cruz or #4595, Cell Signaling), ZFPM1 462 
(sc-9361, Santa Cruz), or RAN (BD Biosciences) a secondary
 
horseradish-conjugated 463 
antibody was added, and a
 
chemiluminescent substrate kit (Roche) was used
 
for detection. 464 
 465 
Isolation of RNA and qantitative PCR (qPCR) 466 
RNA was purified using spin column kits (Qiagen or Macherey-Nagel). cDNA was generated 467 
using the Sprint Powerscript System (Clontech) or MMLV-RT (Promega). qPCR was carried 468 
out by using Sybrgreen PCR Mastermix (Eurogentec) and evaluated according to the standard 469 
curve method. All RNA expression data were normalized to 36B4 (RPLP0). 470 
 471 
Affymetrix Microarray and heatmaps 472 
Affymetrix microarray analysis (Mouse Gene 1.1ST, GeneTitan system) and statistical 473 
evaluation was performed at the Nutrigenomics technology platform of the University of 474 
Wageningen. Row-normalized heatmaps were generated by the Heatmap Builder (69). 475 
 476 
Whole mount embryo staining and histology  477 
Staining was performed according to a published method (70) with minor modification. 478 
Pregnant females were sacrificed at E18.5. Embryos were skinned and eviscerated, fixed in 479 
100% EtOH for 6 hours, stained in 150 mg/l Alcian blue 8 GX (Sigma) for up to 20 hours and 480 
incubated in 100% EtOH overnight. Initial clearing was conducted by incubating the embryos 481 
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in 2% KOH for 6 hours. Follow-up staining of calcified tissue was done in 50 mg/l Alizarin 482 
Red S (Sigma) in 2% KOH for 3 hours. Embryos were sequentially cleared in 2%-0.2% KOH 483 
and stored in 100% glycerol. For histology, limbs from 10-12 weeks or 6 months old mice 484 
were fixed in 4% PFA, decalcified with Osteosoft (Merck) and paraffinized. 1.5-3 µm 485 
sections were stained with Alcian blue 8GX and nuclear fast red (Sigma) as counterstain for 486 
growth plate analysis, or with Naphtol AS-MX phosphate (Sigma) and haemalum as 487 
counterstain for tartrate-resistant acid phosphatase (TRAP). Osteoclast numbers were 488 
quantified by counting multinucleated (n≥3), TRAP-positive cells in the proximal tibia using 489 
a Keyence BZ-9000 microscope and ImageJ software. Growth plate height analysis was 490 
performed by calculating the mean height from 100 randomly assigned perpendicular 491 
distances between the resting and hypertrophic cartilage zones across the complete growth 492 
plate in ImageJ. 493 
 494 
Bone metabolic rate analysis  495 
For dynamic histomorphometry analysis, 10 weeks old male Gata2 (fl/fl) Prx1-Cre 496 
negative/positive mice were injected intraperitoneally with 30 µg calcein/g mouse at two time 497 
points (9 and 2 days before sacrificing). Tibiae were collected, cleared of soft tissue and fixed 498 
in 4% PFA for two days. Samples were washed and dehydrated gradually in 70%, 80%, 90% 499 
to 100% EtOH during a period of 12 days. Technovit 9100 system (Kulzer) was used for 500 
infiltration and polymerization. Calcein double labelling was captured with the Keyence BZ-501 
9000 fluorescence microscope and analyzed by an ImageJ macro (71). Exclusion criteria were 502 
predefined as lack of two distinguishable fluorescent calcein labels. Mineral apposition rate 503 
(MAR) was calculated according to international standards (72). 504 
 505 
Bone µCT and analyses 506 
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Bone µCT analysis was adapted from our previously used method (73). Dissected hind limbs 507 
of 10-12 weeks old male or 8 months old male mice were pruned of soft tissue and scanned 508 
on a VivaCT 40 platform (SCANCO Medical AG) using a voxel size of 10.5 µm, E=70 kV, 509 
I=114 µA and an integration time of 381 ms. Histomorphometric analysis for metaphysis, 510 
proximal, and mid-diaphysis regions was performed using SCANCO Medical software and 511 
the BoneJ-plugin (74) for ImageJ software. 512 
 513 
Biomechanical bone testing  514 
Biomechanical whole bone strength was studied in femora from 10-12 weeks and 6 months 515 
old male mice in destructive three-point bending experiments using a LM 1 ElectroForce Test 516 
Bench (Bose). Explanted femora were mounted anterior side up for bending tests at a 8.5 mm 517 
span width between the end supports. The load was applied to the anterior midshaft of the 518 
femur at a constant deflection rate of 0.1 mm/s. Load (50 lbs / 225 N load cell) and 519 
displacement data were sampled at 100 Hz. Stiffness, maximum load, load to failure and 520 
deflection at failure at fracture were calculated from the force-deflection curve using a routine 521 
written in MATLAB (The Mathworks, Inc.). 522 
 523 
Bone fracture healing model 524 
The fracture healing model was performed as described previously (29). Briefly, eight months 525 
old male mice were given an analgetic (MediGel, ClearH2O) starting two days prior to 526 
surgery. At the day of surgery mice were anesthetized and a steel pin (diameter 0.35 mm) was 527 
inserted into the medullary cavity through a small cutaneous incision at the knee joint for 528 
stabilization followed by a fracture induction with scissors 0.5 cm distal from the knee. 14 529 
days after fracture induction, tibiae were harvested for analyses. After removal of the pin, the 530 
extracted tibiae were fixed and a µCT analysis was conducted. Subsequently, tibiae were 531 
decalcified followed by paraffin embedding and sectioning at 3 mm per slice. Samples were 532 
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stained using SafraninO/Fast green and Movat Pentachrome. ImageJ software was used for 533 
computer-assisted histomorphometric analysis of fracture calluses. Six representative sections 534 
of each callus were analyzed for bone, fibrous and cartilaginous tissue areas in a blinded 535 
manner. 536 
 537 
Data accessibility 538 
GATA2 ChIP-seq data for 3T3-L1 and C3H10T1/2 cells and Affymetrix microarray data of 539 
primary cells over-expressing GATA2 are available at the GEO database under the accession 540 
code GSE101592. 541 
 542 
Statistical analysis 543 
Significance was determined by the 2-tailed Student’s t test or ANOVA, as appropriate, and P 544 
< 0.05 was deemed significant (*P < 0.05). Representative results of at least three 545 
independent cell culture experiments are shown and presented as mean ± s.d. Mouse data are 546 
presented as mean ± s.e.m. 547 
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FIGURE LEGENDS 817 
 818 
Fig. 1 GATA2 binds at canonical WGATAR-motifs in the genome of 3T3-L1 cells and is 819 
enriched near genes involved in skeletal development. (A) GATA2 protein expression in 3T3-820 
L1 preadipocytes (Day 0) and adipocytes (Day 14 after the initiation of differentiation) 821 
determined by immunoblotting. RAN protein served as loading control. (B) Zfpm1 mRNA in 822 
3T3-L1 preadipocytes and adipocytes was analyzed by qPCR. (C) GATA2 was retrovirally 823 
over-expressed in 3T3-L1 cells and protein expression of GATA2 and ZFPM1 determined by 824 
immunoblotting. RAN protein served as loading control. (D) Chromatin immunoprecipitation 825 
(ChIP) of endogenously expressed GATA2 in undifferentiated and differentiated 3T3-L1 826 
revealed preadipocyte-specific binding of GATA2 to the Zfpm1 gene locus (+0.7 kb). (E) 827 
Genomic localization of the 1,975 GATA2 binding sites in 3T3-L1 cells called by the MACS 828 
algorithm. (F) Top 3 enriched de novo motif clusters identified by SeqPos. (G) Identification 829 
of E-box motifs in GATA2 bound regions by de novo motif analysis with SeqPos (top panel). 830 
Top four clusters of known transcription factor motifs enriched in GATA2 binding sites 831 
determined by SeqPos (bottom panel). (H) PhastCons evaluation of GATA2 binding sites for 832 
evolutionary sequence conservation. (I) Gene ontology (GO) analysis of nearest genes (±70 833 
kb of binding sites, n=2,230 genes) showing the term for ‘skeletal system development’ (n=56 834 
genes, Table S1) genes represented among the top ranked clusters. Data are presented as mean 835 
± s.d. and *P < 0.05  836 
 837 
Fig. 2 Cell type-specific binding of GATA2 in mesenchymal and hematopoietic cells. (A) 838 
Intersection of nearest genes (±70 kb of binding sites) between mesenchymal 3T3-L1 and 839 
hematopoietic FDCPmix (mHSC) cells. (B) Average profile of the ChIP-seq signal of the 840 
indicated chromatin marks and DNase I hypersensitivity (DHS) in 3T3-L1 preadipocytes 841 
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around GATA2 binding sites. (C) GO analysis of cell type-specific or overlapping nearest 842 
genes from (A) showing the top two ranked clusters. The corresponding cell type-specific 843 
peaks were analyzed for known transcription factor binding motifs besides the GATA motif 844 
(right panel). (D) GATA2 binding in C3H10T1/2 cells near Zfpm1 and Ccna1 is conserved 845 
and ChIP-seq identified 1,517 peaks and WGATAR as the most enriched motif (de novo). 846 
51% of nearest genes (±70 kb of binding sites) in C3H10T1/2 cells overlapped with those in 847 
3T3-L1 cells. (E) Heatmap visualization of genome wide GATA2 read coverage between 848 
3T3-L1, C3H10T1/2 and FDCPmix cells. In (D), data are presented as mean ± s.d. and *P < 849 
0.05  850 
 851 
Fig. 3 Ectopic expression of GATA2 in MSCs blocks osteoblast differentiation and interferes 852 
with BMP-driven SMAD activation. (A) C3H10T1/2 cells were infected with empty-or 853 
GATA2-expressing retroviruses and Gata2 mRNA levels determined by qPCR and then 854 
induced to differentiate into osteoblasts. 8 days later, differentiation was assessed by (B) 855 
alkaline phosphatase (ALPL) staining and calcium precipitation by Alizarin and (C) the 856 
expression of osteoblast marker genes by qPCR. (D) and (E) Undifferentiated C3H10T1/2 857 
cells described in (A) were transfected with (D) SMAD1/5/8-RE or (E) TCF/LEF-RE-driven 858 
reporter vectors, stimulated with 300 ng/ml BMP2 or 32 mM LiCl as indicated, and luciferase 859 
activity determined. (F) sqWAT-derived Lin-Sca+ cells were infected as described in (A) and 860 
Gata2 mRNA levels determined. (G) Cells described in (F) were analyzed by Affymetrix 861 
gene expression profiling. Expression of GATA2-bound genes (±70 kb of binding sites) 862 
mapped to GO skeletal morphogenesis and development-related pathways (n=102 genes) was 863 
visualized by a heatmap. Gene symbols are given for genes up-or down-regulated (n=41, q < 864 
0.05). (H) Heatmap of selected genes involved in SMAD signaling. Cells were induced to 865 
differentiate into osteoblasts. 8 days later, differentiation was assessed by (I) ALPL staining 866 
and calcium precipitation by Alizarin and (J) the expression of osteoblast marker genes by 867 
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qPCR. Data are presented as mean ± s.d. and *P < 0.05 of Retro GATA2 vs. Retro empty, (D 868 
and E) #P < 0.05 of BMP2 and LiCl treatment vs. untreated Retro empty. 869 
 870 
Fig.4 MSC-specific deletion of GATA2 in mice increases the number of bone-residing 871 
precursor and promotes their osteoblastogenic differentiation in vitro. (A) Lin- Sca1+ cells 872 
from various tissues of mesenchymal origin from Prx1-Cre positive/negative mice with floxed 873 
Gata2 alleles were isolated and analyzed for expression of Gata2 by qPCR (n=4,4). (B) 874 
Deletion of GATA2 protein in sqWAT-derived Lin- Sca1+ cells was validated by 875 
immunoblotting. (C) Lin- Sca1+ cells with or without Gata2 expression were analyzed for a 876 
compensatory up-regulation of other GATA factors by qPCR (n=4,4). (D) Relative abundance 877 
of adipogenic (Lin- Sca1+) and osteoblastic (Lin- Sca1- Pdgfra+) precursors isolated from 878 
bone of Prx1-Cre positive/negative mice with floxed Gata2 alleles (n=14,11). (E) 879 
Ostoblastogenesis of Lin- Sca+ cells derived from bone was assessed by Alizarin staining of 880 
calcium precipitation and (F) the expression of osteoblast marker genes by qPCR (n=3,3). (G) 881 
Ostoblastogenesis of Lin- Sca1+ Pdgfra+ cells derived from bone was assessed by Alizarin 882 
staining of calcium precipitation and (H) the expression of osteoblast marker genes by qPCR 883 
(n=3,3). Data are presented as mean ± s.d. (mean ± s.e.m. in D) and *P < 0.05 between Cre 884 
(+) and Cre (-) cells or mice. 885 
 886 
Fig. 5 MSC-specific deletion of GATA2 impairs trabecular bone structure and bone durability 887 
in aged mice. (A) E18.5 Prx1-Cre positive/negative embryos with floxed Gata2 alleles were 888 
stained with Alizarin red and Alcian blue to assess mineralization and cartilage pattern (top). 889 
Alcian blue staining of longitudinal sections of proximal tibiae growth plates and height 890 
quantifications from three months old mice (bottom, n=5,6). (B) µCT analyses of 1-891 
metaphysis, 2-proximal, and 3-mid diaphysis of tibiae from three months old mice. (C) 892 
Histomorphometric analysis of the medulary cavity of proximal diaphysis for bone surface 893 
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and trabeculae numbers in three months old mice of the indicated genotypes (n=6,6). (D) 894 
Three-point-bending of tibiae from three (n=4,4) and six (n=7,4) months old mice of the 895 
indicated genotypes. Data are presented as mean ± s.e.m. and *P < 0.05 between Cre (+) and 896 
Cre (-) mice. Scale bars: (A, top) 2.5 mm, (A, bottom) 100 µm, (B, left) 1 mm, (B, right) 0.5 897 
mm. 898 
 899 
Fig. 6 MSC-specific deletion of GATA2 affects bone turnover and blood cell counts. (A) 900 
Assessment of the mineral apposition rate (MAR) by quantification of double calcein-labeled 901 
trabecular sections of tibial bones of three month old mice (n=4,5). (B) Bone marrow-free 902 
femora of six months old mice with floxed Gata2 alleles and the indicated genotype were 903 
analyzed for osteoclast marker gene expression by qPCR (n=3,3). (C) Tartrate-resistant acid 904 
phosphatase (TRAP) staining and quantification in proximal tibiae of six months old mice of 905 
the indicated genotype (n=4,4). (D) mRNA expression of Rankl, Csf1, and Opg in the material 906 
described in (B) were determined by qPCR. (E) GATA2 binding near Tnfrsf11b (=Opg) gene 907 
locus in mesenchymal (C3H10T1/2) and hematopoietic cells (FDCPmix) shown in the UCSC 908 
Genome Browser. (F) ChIP-qPCR validation of GATA2 binding upstream (-13.0 and -75.4 909 
kb) of the Opg TSS in C3H10T1/2 cells. (G) Bone-derived Lin- Sca1+ precursor cells, 910 
isolated from mice with floxed Gata2 alleles, were infected with GFP or Cre-expressing 911 
adenoviruses. Opg mRNA expression was determined 96 hours later by qPCR. (H) Blood cell 912 
analysis of six-nine months old Prx1-Cre positive/negative mice with floxed Gata2 alleles 913 
(n=25,20). In (A-D), data are presented as mean ± s.e.m., in (F) and (G) data are presented as 914 
mean ± s.d., and *P < 0.05. Scale bars (A): 25 µm, (C): 50 µM 915 
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